Creative Diagnostics Launches Anti-MMAE Antibodies for PK/PD Studies on MMAE-ADC
As a global leading supplier of of raw materials, antibodies, and reagents for bio-technology industry, Creative Diagnostics has recently launched a serial of Anti-MMAE antibodies with high affinity and specificity that are designed for use in an ELISA environment, and can be applied in PK/PD studies of MMAE-ADC.
MMAE (Monomethyl auristatin E) is a synthetic antineoplastic agent. Because of its toxicity, it cannot be used as a drug itself, instead, it is linked to a monoclonal antibody which directs it to the cancer cells. Antibody-drug conjugates (ADCs) are regarded as a powerful immunotherapy that can accurately eliminate cancers without damaging normal tissues. However, their enormously potent toxins pose a challenge for researchers to develop the corresponding antibodies before the animal immunization and clinical trials.
For the sake of a more competent method to facilitate the pharmacokinetics (PK) and pharmacodynamic (PD) evaluation of newly developed ADCs, Creative Diagnostics has developed anti-MMAE antibodies and paired conjugates that are suitable for ADC ELISA assay development. It can be used in the quantitative determination of ADC level in test sample, thereby greatly saving the time and costs.
Various products are released including Anti-MMAE monoclonal antibody, clone 3F3(CABT-B8992), Anti-MMAE monoclonal antibody, clone 3F3 [Biotin](CABT-B8993), MMAE [BSA](DAG603S), MMAE [HRP] (1:1)(DAG605S) and MMAE [HRP] (2:1)(DAG606S). For MMAE [HRP] (1:1), this HRP-MMAE conjugate is designed with similar linker chemistry as ADC and is synthesized at Creative Diagnostics for our customers' usage in horseradish peroxidase (HRP) based assay. A long flexible PEG linker is also incorporated in the conjugate to retain the activity of HRP and MMAE binding. The final conjugate is purified to obtain a single MMAE-labeled HRP conjugate, and is lyophilized from PBS containing sugar-based stabilizer for easy shipping and storage.
"Our Anti-MMAE antibodies are featured with high purity and lot consistency, and are validated in ELISA development, which can react with MMAE and MMAE-antibody drug conjugate. There are no cross-reaction with other ADC analogs. In addition, we're proud to announce that a new set of antibodies specific to cytotoxic drugs are also now commercially available. Using these newly launched antibodies, we are able to successfully develop highly sensitive MMAE and MMAF ELISA kits." said Dr. Jessica Waldorf, chief scientific officer of R&D department of Creative Diagnostics.
"This new addition to the antibodies portfolio is suitable for applications in ADC ELISA assay development, and we're glad to provide such resource to enable the scientific research community to better proceed the ADC research and support their efforts to develop solutions for diseases." said Prof. Mike Knuth, M.D., the chief scientific officer of R&D department of Creative Diagnostics.
If you want to know more details about Anti-MMAE antibodies and conjugates or other research materials, please visit Creative Diagnostics at https://www.creative-diagnostics.com/.
About Creative Diagnostics
Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components and critical assay reagents. It also provides contract biologic R&D and manufacturing services to the diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market. It aims to provide a trusted source for all researchers' assay development and manufacturing needs.